A systematic review of strategies to improve appropriate use of opioids and to reduce opioid use disorder and deaths from prescription opioids

Andrea D. Furlan, Nancy Carnide, Emma Irvin, Dwayne Van Eerd, Claire Munhall, Jaemin Kim, Cathy Meng Fei Li, Abdul Hamad, Quenby Mahood, and Sara MacDonald

Institute for Work & Health, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada; University Health Network, Toronto, Ontario, Canada

ABSTRACT

Background: Abuse of prescription opioids is a serious problem in North America.

Aims: The aim of this study was to conduct a systematic review of peer-reviewed and grey literature to examine existing strategies aimed at improving the appropriate use of prescription opioids and/or reducing the misuse, abuse, and diversion of these drugs.

Methods: The following electronic databases were searched to September 2015 without language restrictions: MEDLINE, EMBASE, PsycINFO, and CINAHL; the grey literature was searched to May 2014. Reference lists of retrieved papers were also searched. Studies were eligible if a strategy was implemented and its impact on at least one of the primary outcomes of interest (appropriate prescription opioid use; misuse, abuse, opioid use disorder, diversion; overdose) was measured. Standardized, prepiloted forms were used for relevance screening, quality appraisal, and data extraction.

Results: A total of 65 studies that assessed 66 distinct strategies were identified. Due to the heterogeneity of the strategies, a qualitative synthesis was conducted. Many studies combined more than one type of strategy and measured various types of outcomes. The strategies with most promising results involved education, clinical practices, collaborations, prescription monitoring programs, public campaigns, opioid substitution programs, and naloxone distribution. We also found strategies that had some unintended consequences after implementation.

Conclusions: Our review identified successful strategies that have been implemented and evaluated in various jurisdictions. There is a need to replicate and disseminate these strategies where the problem of prescription opioid misuse and abuse has taken a toll on society.

RÉSUMÉ

Contexte: L’abus d’opioïdes sur ordonnance est un problème grave en Amérique du Nord.

But: Effectuer une revue systématique de la littérature examinée par des pairs et de la littérature grise afin d’étudier les stratégies existantes pour améliorer l’usage approprié des opioïdes sur ordonnance ou réduire la mauvaise utilisation, l’abus ou le détournement de ces médicaments.

Méthodes: Des recherches ont été effectuées sans aucune restriction de langue dans les bases de données électroniques suivantes : MEDLINE, EMBASE, PsycINFO et CINAHL jusqu’en septembre 2015 et dans la littérature grise jusqu’en mai 2014. Des recherches ont aussi été effectuées dans les listes de références des articles retenus. Les études étaient admissibles si une stratégie avait été mise en œuvre et que son effet sur au moins un des principaux résultats étudiés (usage approprié des opioïdes sur ordonnance; mauvaise utilisation, abus, trouble de consommation ou détournement des opioïdes; surdose) avait été mesuré. Des formulaires normalisés et préalablement mis à l’essai ont été utilisés pour déterminer la pertinence et évaluer la qualité des études, et en extraire les données.

Résultats: Au total, 65 études évaluant 66 stratégies distinctes ont été répertoriées. En raison de l’hétérogénéité des stratégies, une synthèse qualitative a été effectuée. De nombreuses études combinaient plus d’un type de stratégie et mesuraient divers types de résultats. Les stratégies dont les résultats étaient les plus prometteurs portaient sur l’éducation, les pratiques cliniques, les collaborations, les programmes de surveillance des ordonnances, les campagnes publiques, les programmes de substitution des opioïdes et la distribution de naloxone. Nous avons également trouvé des stratégies qui avaient eu des conséquences imprévues après leur mise en œuvre.
Introduction

Abuse of prescription opioids is a serious health and safety problem in North America. In the United States, more than 165,000 people died of overdose related to opioid pain medications between 1999 and 2014.\(^1\) In Canada, after a record-breaking year of apparent opioid-related deaths in 2016 (2861 deaths), the Public Health Agency of Canada predicts the number of Canadians that died from opioid overdoses will surpass 4000 by the end of 2017.\(^2\)^\(^3\)

Overprescribing of opioids by health care professionals has been implicated as the root cause of the current crisis. In Canada, there were more than 21.5 million opioid prescriptions filled in 2016 alone, with an increasing proportion of strong opioids among all opioids dispensed.\(^4\) On the other hand, the Position Statement from the Canadian Pain Society recognizes that essential use disorders, including primary care delivery models for treating opioid use disorders, and diversion. The knowledge users interested in this topic are not limited to health care professionals but rather are representatives of diverse groups within our communities, including public health, prevention services, government, law enforcement, regulators, and insurance payers, all of whom are interested in programs, strategies, policies, and regulations to solve the problem of inappropriate opioid use. A few recent systematic reviews have synthesized the evidence for narrow and specific types of strategies, including primary care delivery models for treating opioid use disorders,\(^5\) supervised dosing versus off-site consumption of opioid substitution treatment,\(^6\) community overdose prevention and naloxone distribution programs,\(^7\)^\(^8\) clinical strategies for reducing aberrant drug-related behavior (e.g., treatment agreements, urine drug testing),\(^9\)^\(^10\) and prescription opioid policies (namely, guidelines and legislation).\(^11\)

Our goal was to conduct a comprehensive systematic review to more broadly identify existing strategies, programs, policies, and practices aimed at improving the appropriate use of prescription opioids and/or reducing the misuse, abuse, and deaths related to these drugs, with a focus on strategies that can be implemented in North America, the epicenter of the current crisis.

Methods

We followed the PRISMA checklist, and the methods for this review have been previously published in Prospero.\(^12\)

The research question addressed in this review included the following components:

**What:** What are the existing strategies, programs, policies and practices aimed at (1) improving the appropriate use of prescription opioids and/or (2) reducing the misuse, abuse, and diversion of these drugs? *Misuse* was defined as taking a medication in a manner or dose other than prescribed; taking someone else’s prescription, even if for a legitimate medical complaint such as pain; or taking a medication to feel euphoria (i.e., to get high). The term *nonmedical use* of prescription drugs also refers to these categories of misuse.\(^13\)

**Who:** There are many organizations and agencies with a keen interest in promoting the appropriate use of and/or reduction of inappropriate use of opioids. However, given limited resources and time to conduct this review, we narrowed the sources of material to four major sectors: (1) health-related professions and regulatory authorities; (2) government, public health/health promotion agencies, prevention and treatment organizations; (3) insurance organizations, including workers’ compensation; and (4) law enforcement agencies. Therefore, we excluded materials produced by military organizations, the pharmaceutical industry, or for-profit organizations. In addition, we excluded Internet-based or media-related strategies.

**Where:** We were interested in materials that are particularly applicable to the current Canadian context.

**When:** In North America, abuse of prescription opioids began to rise with the introduction of
Oxycontin in 1996. Therefore, we focused on studies published in the 20 years after the release of Oxycontin.

**Searches**

To identify peer-reviewed publications, we searched the following electronic bibliographic databases from inception to September 2015 with no language restrictions: MEDLINE, EMBASE, PsycINFO, and CINAHL. All search strategies were developed by the research team in consultation with the knowledge users group and executed by an experienced librarian. The search strategies were adapted from the P.I.C.O. structure (Patient, Intervention, Comparison, and Outcomes) of reviews of effects of interventions. The controlled vocabulary differs significantly across peer-reviewed databases. Therefore, search terms were customized for each database. The search strategies are shown in Appendix 1.

It was also anticipated that many relevant studies would not be published in peer-reviewed journals. We addressed this gap by also systematically searching the grey literature. The grey literature is a rich source of material that is not controlled by commercial publishing but offers advantages of usually being more current, free, relevant, unique, and on nonmainstream topics or aspects. For grey literature, Canadian websites for the following groups were searched (Appendix 2): regulatory authorities for health-related professionals (e.g., colleges for physicians, pharmacists, and nurses), government (federal and provincial), public health and health promotion agencies, prevention and treatment organizations, workers’ compensation boards, private insurance companies, and law enforcement agencies. There were no language restrictions. However, for feasibility, only materials uploaded, updated, or available in the previous 20 years were searched.

**Eligibility criteria**

The following primary opioid-related outcomes were considered eligible for inclusion:

(1) Appropriate prescription of opioids for pain measured by pain intensity or functional improvement, number of high-dose opioid prescriptions, intermittent use of long-acting opioids, combination with benzodiazepines, appropriate education provided to patient, appropriate selection of patients for opioids, and appropriate monitoring of patients on opioids.

(2) Misuse, abuse, opioid use disorder, and diversion of prescription opioids.

(3) Fatal or nonfatal opioid-related overdoses.

A secondary outcome of interest was unintended consequences of the implemented strategy. These could be adverse consequences to participants (e.g., being harassed by the police because they were carrying naloxone; additional burden on the clinical staff) or to society (e.g., shifting the opioid crisis to a neighbor region where the strategy had not been implemented).

Only studies with empirical data evaluating the effectiveness of strategies on our outcomes of interest were included in this review. These could be quantitative (observational or experimental), qualitative, or mixed-method studies. For grey literature, we included data evaluations, foundation reports, government reports, granteepublications, noncommercially published conference papers, reports, special reports, and working papers, committee reports, testimony, and conference proceedings.

All strategies that have been developed, implemented, and evaluated in North America, Europe, and Australia/New Zealand were eligible for inclusion. Strategies that have been implemented outside of these regions were only included if they were applicable or useful to the opioid-related issues in Canada (i.e., if the country had trends in prescription opioid use and misuse similar to those in Canada and/or the country has a health care system similar to Canada).

**Relevancy screening**

Titles and/or abstracts of the studies retrieved were screened independently by rotating pairs of reviewers using the full set of inclusion/exclusion criteria and a standardized, prepiolteform using Distiller SR software. The full text of studies meeting all criteria or where there was uncertainty were retrieved and assessed for relevancy by rotating pairs of reviewers. Any disagreements were resolved through discussion with reviewer pairs and a third reviewer was consulted when consensus could not be reached.

**Data extraction**

A standardized, prepiolteform was used to extract data from the included studies for evidence synthesis. Data were extracted according to the variables that have been agreed upon by the team members for all papers included in this review, which included country, settings, target population, group that developed the strategy, components of the strategy, duration, outcomes,
and results. During the process of data extraction, we met regularly to resolve issues related to locating the data in the text, establishing the nature and type of the data, ascertaining reliability of data extraction, and checking data extraction in preparation for analysis.

Quality appraisal

To assess the quality of each included study, we first applied a classification by methodological design:

- Group A: Evidence from randomized studies.
- Group B: Evidence from controlled experimental studies without randomization or from epidemiological studies (cross-sectional, cohort, or case-control analytic studies).
- Group C: Evidence from comparisons between times or places with or without the intervention; dramatic results in uncontrolled experiments or qualitative statements could be included here.

Second, a critical appraisal checklist was used to assess risk of selection, performance, detection, attrition, and reporting bias in each study (Appendix 3). The risk of bias assessments was entered in RevMan software version 5.3.22

Data analysis and synthesis

Empirical data included both quantitative and qualitative evaluations of the impact of the strategy on any of the outcomes described above. Quantitative data were analyzed as differences between groups (for studies in groups A and B) or within groups (for studies in group C). We calculated standardized effect sizes of interventions that yielded statistically significant results: Cohen’s $d$ for main differences,23 Cohen’s $d$ from $t$ statistics,24 Cohen’s $d$ from $F$ test,25 Cohen’s $h$ for differences in proportion,26 Hedge’s $g$ from $t$ statistics when sample size was less than 30,27 and logit $d$ from odds ratio.26,28,29 (Appendix 4).

For studies with multiple outcomes, we reported the measured outcome with the largest effect size for each of the three outcomes of interest. The effect size was expressed as a negative or positive value, indicating that the intervention either had a smaller or greater effect than the control, respectively. The effect sizes were grouped into categories of no (0–0.19), small (0.20–0.49), medium (0.50–0.79), or large (0.8 or larger) effect.30 In the graphical representations, no effect was assigned a value of 0, small was assigned 1, medium 2, and large 3. When the data were only reported as a qualitative statement, we assigned its impact factor (0, 1, 2, or 3) based on similar studies from which we had calculated the effect size. The association between number of contents in each strategy and the impact factor was calculated using correlation coefficient for each outcome. Rather than a meta-analysis, we conducted a narrative synthesis to describe the interventions and a quantitative analysis to assess the impact of each intervention.

Results

The searches of electronic databases yielded 5169 titles and abstracts and searches of the grey literature yielded 72 studies (Figure 1). A total of 557 full texts were obtained from the electronic databases and grey literature. Of these, 65 met the inclusion criteria and were included: 9 randomized trials31–39 and 56 nonrandomized studies.40–95 One study described two strategies and provided separate results.38 The characteristics of population, strategies, outcomes, and unintended consequences are shown in Appendix 5. The target population for the strategies was grouped into three groups: (1) patients and opioid users, (2) health care providers, and (3) the general public.

Critical appraisal of the studies

Overall, randomized trials and nonrandomized studies had significant methodological shortcomings. Among the nine randomized trials, the most common types of bias were performance (blinding of participants and personnel) and detection bias (blinding of outcome assessment; Figure 2). There was a potential for selection bias in approximately half of the trials due to unclear methods of randomization and allocation concealment. One study had a high risk of attrition bias due to a 39% drop out rate and one study had a high risk of bias due to potential for conflict of interest.32 There was no indication of reporting bias in any of the trials included.

Among the 56 nonrandomized studies, the most frequent methodological flaws were lack of a separate control group, lack of description of how groups were formed, lack of description of pre-intervention characteristics, lack of examination of whether important differences existed between the remaining and dropout participants, lack of documentation of participation (compliance with the intervention), poor reporting of main outcomes measurements at baseline, lack of adjustments for pre-intervention differences, and statistical methods of analysis that were not optimal.
The majority of studies had a clear research question, a clear description of the strategy (or intervention process), a clear documentation of the effects of the intervention on some of the exposure parameters, and length of follow-up of 3 months or greater. For some methodological indicators, most studies lacked clear description and therefore the judgments were “unclear”: whether participation rate was at least 50%, whether loss to follow-up was less than 35%, whether the analysis considered the participants in the groups they were originally allocated, and whether there was a direct between-group comparison or not.

**Target population of the strategies**

Forty-eight strategies were aimed at only one target group, 15 were aimed at two target groups, and three were aimed at all three target groups of interest.
The most common target group was health care professionals: as a single target in 33 strategies and combined with opioid users in 11 strategies.

Content of the strategies

The content of the strategies was categorized into educational, clinical practice, naloxone distribution, opioid substitution therapies, prescription monitoring, campaigns to return unused opioids (take-back programs), regulations, policies, and public campaigns. A strategy could have more than one type of content: one strategy had five contents, 77 3 strategies had four, 44, 67, 81 13 strategies had three, 41, 42, 43, 44, 46, 47, 48, 51, 52, 53, 54, 55, 56, 57, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96 29 strategies had two, 31, 32, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 52, 53, 54, 55, 56, 57, 59, 60, 61, 62, 63, 64, 65, 66, 67, 70, 72, 74, 77, 79, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96 and 20 strategies had a single content.

The association between the number of contents and the impact factors was small for all three outcomes of interest: 0.32 for appropriate use, 0.08 for misuse, and 0.14 for overdose. The contents of each strategy are explained below:

- Education. These strategies involved formal teaching to improve knowledge or training to impart specific skills. Examples of educational strategies were attending a workshop or a continuing medical educational event. 65 Thirty-five strategies involved education.

- Clinical practice. These strategies involved changes in how health care was delivered, such as implementation of recommendations from clinical practice guidelines, 87 using a tool to improve opioid prescribing, 86 implementing urine drug tests, 85 or using disease management programs. 86 Thirty-two strategies involved clinical practice changes.

- Reversal of overdose with naloxone involved distribution of naloxone to caregivers or bystanders with the potential to reverse an opioid-related overdose. An example was an intervention that included not only distribution of naloxone but
also an educational campaign to identify high-risk individuals. Nine strategies involved naloxone distribution.

- Opioid substitution therapies were carried out by healthcare professionals who prescribe methadone or buprenorphine for opioid use disorder and dependence. This type of strategy was usually combined with clinical or educational strategies. Six strategies involved opioid substitution therapies.

- Take-back program involved reducing the amount of unused opioids in households and preventing diversion by providing drop-boxes and incentives for safe disposal of the medications. Only one study was included.

- Prescription monitoring or review programs (PMPs) are strategies that use an electronic system to keep track of opioid prescriptions by physicians or opioid dispensing by pharmacists. They were usually combined with education, changes in clinical practices, or regulations. Eighteen strategies involved PMPs.

- Regulations and policies are strategies that use legislation or policies to correct or incentivize certain behaviors. It could be the sole content of a strategy or it could be combined with education, prescription monitoring program, or public campaigns. Sixteen strategies involved regulations or policies.

- Community or public health campaigns included strategies aimed at prevention or public health strategies. Seven strategies (reported in five studies) involved community or public health campaigns.

- Collaborative strategies involved bringing diverse groups of people together to solve a common issue or to improve a situation, such as an interprofessional or multidisciplinary team. Ten strategies included collaboration as a key component of their strategies.

**Impact on the strategies**

**Impact on appropriate use of opioids**

Twenty-six studies measured the impact of a strategy on improving or ensuring appropriate use of opioids (Table 1). The impact factors ranged from −2 to 3. The only strategy with a negative impact involved a comparison of a PMP between two states in the United States. Researchers found that in suspected diversion or doctor shopping, the health care providers using PMPs were 53% less likely to discuss the concerns with the patient and 73% less likely to state to the patient that they were out of stock of the medication. Eight strategies had no effect on appropriate use of opioids, seven strategies had a small positive effect, six strategies had a moderate positive effect, and four strategies had a large positive effect, which included (1) Project Lazarus, a community activation and coalition-building, monitoring, and surveillance data, prevention of overdoses, and use of rescue medication for reversing overdoses and evaluation of the program; (2) implementation of a treatment agreement developed with cooperation of anesthesiologists, psychologists, nurses, rehabilitation specialists, and clinical pharmacists; (3) a clinic-wide strategy including opioid prescribing policies and protocols, guidelines to address depression and substance abuse screening, drug selection, dose titration, urine toxicology testing, review of the PMP database and agreement violations, in addition to a monthly meeting with a multidisciplinary committee to review protocols and discuss cases and provider education; and (4) a multifaceted education initiative regarding pethidine, tramadol, and morphine prescriptions consisting of in-services and feedback by clinical pharmacists, literature discussion, and posters.

**Impact on misuse, abuse, opioid use disorder (addiction), and diversion**

Forty studies measured the impact of the strategy on outcomes of misuse, abuse, opioid use disorder, and/or diversion (Table 1). The impact factors ranged from −1 to 3. The only strategy with a negative impact on this outcome was a 1-h educational group session on the nature, theories, and treatment of pain provided by a clinical psychologist for new patients. The aim of the intervention was to reduce violations of the opioid treatment agreement. The results showed that those who attended the educational session were 1.8 times more likely to be discharged due to violation of the treatment agreement, and the explanation was that participants in the educational session could perceive a false sense of privilege because they had participated in their care beyond a typical first physician office visit. Sixteen strategies had no effect on this outcome, ten strategies had a small positive effect, six strategies (seven studies) had a moderate positive effect, and seven had a large positive effect.
| Study | Category of outcome | Measured outcome | Derived effect size measure | Effect size | Impact factor |
|------|-------------------|----------------|---------------------------|-------------|--------------|
| Lamb et al. 2007 | Appropriate use | Prescription claims per member | Logit | 0.07 | 1.87 |
| Wender et al. 2007 | Misuse, abuse, and addiction | Mortality rates from opioids | Logit | 0.15 | 1.87 |
| Bujo et al. 2012 | Misuse, abuse, and addiction | Overdose and deaths | Logit | 0.54 | 0.74 |
| Cochella and Bateman 2012 | Misuse, abuse, and addiction | Discharged with opioids | Logit | 0.67 | 1.87 |
| Dormuth et al. 2012 | Misuse, abuse, and addiction | Overdose and deaths | Logit | 0.49 | 0.74 |
| Manchikanti et al. 2006 | Appropriate use | Patients referred to methadone | Logit | 0.01 | 0.01 |
| Spoth et al. 2013 | Misuse, abuse, and addiction | Change in pain scores | Logit | 0.32 | 0.74 |
| Thomas et al. 2013 | Misuse, abuse, and addiction | Pain complaints | Logit | 0.57 | 0.74 |
| Pade et al. 2012 | Misuse, abuse, and addiction | Death rates from opioids | Logit | 0.02 | 0.01 |
| Stover 2010 | Appropriate use | Mortality rates from opioids | Logit | 0.54 | 0.74 |
| Wheeler et al. 2012 | Misuse, abuse, and addiction | Overdose and deaths | Logit | 0.01 | 0.01 |
| Albert et al. 2011 | Appropriate use | Discharged with opioids | Logit | 0.00 | 0.00 |
| Barry et al. 2015 | Appropriate use | Discharged with opioids | Logit | 0.00 | 0.00 |
| Davis 2015 | Appropriate use | Discharged with opioids | Logit | 0.00 | 0.00 |
| DiPaula and Menachery 2015 | Appropriate use | Discharged with opioids | Logit | 0.00 | 0.00 |
| Dwyer et al. 2013 | Appropriate use | Discharged with opioids | Logit | 0.00 | 0.00 |
| Gugelmann et al. 2013 | Appropriate use | Discharged with opioids | Logit | 0.00 | 0.00 |
| Johnson et al. 2014 | Appropriate use | Discharged with opioids | Logit | 0.00 | 0.00 |
| Katzman et al. 2014 | Appropriate use | Discharged with opioids | Logit | 0.00 | 0.00 |
| Paone et al. 2015 | Appropriate use | Discharged with opioids | Logit | 0.00 | 0.00 |
| Saitz et al. 2014 | Appropriate use | Discharged with opioids | Logit | 0.00 | 0.00 |
| Kunins 2015/Larochelle et al. 2015 | Appropriate use | Discharged with opioids | Logit | 0.00 | 0.00 |

(Continued)
Table 1. (Continued).

| Study                                      | Measured outcome                                                                 | Category of outcome                | Derived effect size measure | Effect size | Impact factor |
|--------------------------------------------|----------------------------------------------------------------------------------|------------------------------------|----------------------------|-------------|---------------|
| James et al. 2014                          | ED patients on extremely high opioid dose (> 1000/mg MEQ)                        | Appropriate use                    | Logit $d$                  | 0.96        | 3             |
| Husk et al. 2014                           | Percentage of ED patients not receiving opioids                                  | Appropriate use                    | Logit $d$                  | 0.06        | 0             |
| Husk et al. 2014                           | Misuse, abuse, and addiction                                                     | Logit $d$                          | 0.04                       | 0           |               |
| Saenger et al. 2013                        | Units of opioid disposals                                                        | Misuse, abuse, and addiction       | Logit $d$                  | 0.37        | 2             |
| Gray et al. 2015                           | Deaths from overdose                                                             | Overdose and death                 | Logit $d$                  | 0.32        | 1             |
| Ringwald et al. 2015                       | Number of opioid users                                                           | Misuse, abuse, and addiction       | Extrapolation               | —           | 1             |
| Garcia et al. 2014                         | Average daily dose of opioids                                                     | Misuse, abuse, and addiction       | Logit $d$                  | 0.08        | 0             |
| Garcia et al. 2014                         | Average pain ratings                                                             | Misuse, abuse, and addiction       | Logit $d$                  | 0.11        | 0             |
| Leece et al. 2013                          | Naloxone administration                                                          | Misuse, abuse, and addiction       | Logit $d$                  | 0.17        | 0             |
| Delcol et al. 2015                         | Deaths from oxycodone                                                            | Misuse, abuse, and addiction       | Logit $d$                  | 0.26        | 1             |
| Naliboff et al. 2011                       | Pain ratings                                                                     | Misuse, abuse, and addiction       | Logit $d$                  | 0.40        | 1             |
| Reifler et al. 2012                        | Intentional opioid exposures                                                     | Misuse, abuse, and addiction       | Logit $d$                  | 0.19        | 0             |
| Franklin et al. 2012                       | Workers on 120 mg/day MEQ                                                        | Misuse, abuse, and addiction       | Logit $d$                  | 0.40        | 1             |
| Taylor et al. 2007                         | Patients on pethidine                                                            | Appropriate use                    | Logit $d$                  | 0.82        | 3             |
| Doe-Simkins et al. 2014                    | Opioid use within last 30 days                                                    | Misuse, abuse, and addiction       | Not statistically significant | —           | 0             |
| Doe-Simkins et al. 2014                    | Actions taken during overdose                                                    | Misuse, abuse, and addiction       | Not statistically significant | —           | 0             |
| Gaston et al. 2009                         | Successful rescue                                                               | Overdose and death                 | Logit $d$                  | 0.22        | 1             |
| McGarty et al. 2004                        | Positive attitude toward buprenorphine                                            | Misuse, abuse, and addiction       | Not statistically significant | —           | 0             |
| Srivastava et al. 2012                     | Physician difficulty with dosing                                                  | Appropriate use                    | Logit $d$                  | 0.54        | 2             |
| Sullivan 2006                              | Methadone prescriptions                                                          | Appropriate use                    | Logit $d$                  | 0.63        | 2             |
| Otto et al. 2009/Zahradnik et al. 2009     | Defined drug dosage                                                             | Misuse, abuse, and addiction       | Logit $d$                  | 0.51        | 2             |
| Jamison et al. 2010                        | Average pain ratings                                                             | Misuse, abuse, and addiction       | Logit $d$                  | 0.38        | 1             |
| Jamison et al. 2010                        | Drug misuse index                                                                | Misuse, abuse, and addiction       | Logit $d$                  | 1.14        | 3             |
| Lofwall et al. 2011                        | Adherence to maximum dose                                                        | Misuse, abuse, and addiction       | Logit $d$                  | 0.46        | 1             |
| Lofwall et al. 2011                        | Percentage of doctors giving 7 days or less of buprenorphine                     | Misuse, abuse, and addiction       | Logit $d$                  | 0.46        | 1             |
| Spoth et al. 2008                          | Lifetime narcotic misuse                                                        | Misuse, abuse, and addiction       | Logit $d$                  | 0.44        | 1             |
| Spoth et al. 2008                          | Lifetime nonprescribed medication use                                             | Misuse, abuse, and addiction       | Logit $d$                  | 0.16        | 0             |
| Spoth et al. 2013                          | Lifetime nonprescription opioid misuse                                           | Misuse, abuse, and addiction       | Logit $d$                  | 0.13        | 0             |
| Burchan and Pagel 1995                     | Good response to treatment                                                       | Appropriate use                    | Logit $h^2$                | 0.89        | 3             |
| Chelminski et al. 2005                     | Pain disability index                                                            | Appropriate use                    | Logit $d$                  | 0.44        | 1             |
| Goldberg et al. 2005                       | Total opioid consumption                                                         | Misuse, abuse, and addiction       | Logit $d$                  | 0.12        | 0             |

*Extrapolation was based on interpretation of qualitative data.

The aim of study was to demonstrate noninferiority rather than superiority of the intervention.

The calculation for effect size assumes that the expected change in the control is 50% of the measured intervention change.

The lowest value in the reported range was used to calculate a conservative estimate of the effect size.

The impact factor is assigned comparatively, using other calculated impact factors of similar strategies as a framework.

The relative risk is used an approximation of odds ratio for logit $d$.

The calculation of tightening estimate assumes equal sample size in the comparison groups.

*Unintentional Poisoning Deaths in Oklahoma, [https://www.ok.gov/health2/documents/UP_Deaths_2007-2012.pdf](https://www.ok.gov/health2/documents/UP_Deaths_2007-2012.pdf).

*The pooled standard deviation assumes equal sample size in the comparison groups.

The study showed mixed results.

*The standard deviation of the intervention group was used as an approximation of the pooled standard deviation.

PO = by mouth; PMP = prescription monitoring program; ER = emergency room; ED = emergency department.
back pain and opioid use disorder; (2) a collaborative practice, with prescription of buprenorphine and naloxone, with weekly urine drug testing; (3) a prescription monitoring program with easy access at the point of care; (4) a structured cognitive behavioral training program for prevention of substance misuse; (5) a law enforcement change in the state of Florida; (6) a recidivism program with staff education for high emergency department users; and (7) a public health initiative involving clinical practice guidelines, media, town halls, public campaigns, and announcements.

**Impact on overdose and deaths**

Twenty-two studies measured the impact of the strategy on outcomes of overdose and death (Table 1). The impact factors ranged from −3 to 3. The strategy with the largest negative impact included the implementation of an opioid dosing guideline (maximum 120 morphine equivalents per day) where there was a marked increase in mortality due to methadone. Ten strategies had a negligible or no impact on overdoses and deaths. Five strategies had a small positive effect, two had a moderate positive effect, and four had a large positive effect, which included (1) overdose prevention training and naloxone distribution, plus a change in the legal status of naloxone to permit its administration by any member of the public; (2) pharmacy-based naloxone distribution plus education and training; (3) First Nations healing strategies plus opioid substitution and primary care involvement; and (4) take-home naloxone and training program.

**Most promising strategies by content and target audience**

Figure 5a and 5b show the impact of the strategies by content and target population. It suggests that the most promising strategies to improve appropriate use of opioids are (1) educational strategies aimed at health care professionals; (2) clinical strategies aimed at patients, opioid users, and health care professionals; and (3) collaborations. The most promising strategies to reduce misuse, abuse, opioid use disorder, and diversion of opioids are (1) educational strategies aimed at patients, opioid users, and health care providers; (2) clinical strategies aimed at patients, opioid users, and health care providers; (3) PMPs; (4) collaborations; (5) public health; and (6) opioid substitution. The most promising strategies to reduce overdoses and deaths are (1) education aimed at patients and opioid users and (2) naloxone distribution.

**Unintended consequences of implemented strategies**

Among the 66 strategies described, 19 (29%) had some type of unintended consequence. It was unclear in 43 studies whether there were any unintended consequences or not.

Consequences that affected the target population of the strategy were reported, such as patients not receiving necessary prescriptions; patients paying for their prescriptions out of their own pockets; overdose due to rotation from other opioids to methadone; more overdose by morphine, hydromorphone, and heroin; stolen naloxone kits; being harassed by police over possession of naloxone; stigma associated with carrying a naloxone kit; stigma associated with receiving a prescription for addiction; a paradoxical increase in overdose because suspension of physicians who were prescribing improperly led to patients on withdrawal and overdosing from other sources; patients had a false sense of privilege because of participation in an educational session, leading to more opioid abuse, and possible beliefs that naloxone access enables addiction to opioids.

There were consequences to the staff involved in the implementation of strategies: extra burden on the clinical staff (pharmacists and/or physicians); burden on pharmacy staff who had to assemble intranasal naloxone kits; or risks of needle stick injury to staff who had to assemble intramuscular naloxone.

Societal consequences included shifting the opioid crisis to a neighboring region where the strategy had not been implemented; higher costs; increase in the proportion of prescriptions of opioids; increase in dose of opioids prescribed; shifting from one opioid to another; increase in use of benzodiazepines and barbiturates; and more patients developing opioid tolerance or filling prescriptions from other sources.

(Fo r details about the unintended consequences reported in each study, see Appendix 5.)

**Discussion**

**Interpretation**

We searched the peer-reviewed and grey literature for studies that implemented and evaluated strategies, programs, policies, and practices to improve the appropriate use of opioids and reduce misuse, abuse, opioid use disorder, diversion, overdoses, and deaths related to opioids. We found 65 studies reporting on 66 distinct strategies. Though the majority of the studies were at
Figure 5. Impact factors by content and target population.
high risk of bias, there is some indication that the most promising strategies involved education, clinical practices, collaborations, PMPs, public campaigns, opioid substitution programs, and naloxone distribution. Twenty-nine percent of strategies reported some sort of unintended consequence.

**Significance**

Misuse and abuse of opioids have become a widespread problem in Canada, but many areas do not yet have the necessary measures in place to address this. This systematic review benefits from the diversity of strategies and outcomes that were implemented and evaluated in various jurisdictions similar to the Canadian context. Knowledge users can refer to this systematic review in the planning stages of implementing interventions to improve the appropriate use of prescription opioids and/or reduce the misuse, abuse, and diversion of these drugs. Knowledge users can also appraise the interventions of interest to make contextually appropriate modifications and combine various strategies to achieve the desired effects. As such, this comprehensive compilation of studies provides a concrete foundation for knowledge users to build upon. Lastly, by appraising the quality of the evidence, we highlight the deficits...
and need for improvement in this body of literature. We encourage knowledge users to engage with the suggestions for future studies to improve the quality of evidence in this field, while incorporating economic feasibility into the growing body of literature.

Limitations

Limitations of the existing literature

The quality of evidence in this body of literature contains many methodological flaws. The majority of studies are observational in nature, with only nine randomized controlled trials among the 65 studies. In addition, most grey literature publications did not provide empirical data. Another limitation was that a minority of studies reported unintended consequences associated with the strategies.

Limitations of the methods used in this review

One limitation of our review is that the literature search was last updated in September 2015. Since then, there have been publications of studies that could potentially be included in this review. We updated the electronic searches up to March 2018 and there were 1427 titles and abstracts. After screening by two authors, there were 182 remaining titles and abstracts that could potentially meet the inclusion criteria for this current review. Another limitation is using assumptions to calculate an effect size (ES). Fourteen studies did not have a separate control for comparison, and this was particularly common in studies on regulation changes. In an effort to avoid overestimating the ES, we assumed the expected change in the control to be 50% of the measured intervention change in these 14 studies. Another limitation is that the impact factor was extrapolated when studies were qualitative in nature or did not provide sufficient data to calculate an ES; this was applied to four studies. Extrapolation relied on both clinical expertise and the completed framework of impact factors as a reference, which introduced some degree of subjectivity into the analysis. Lastly, studies could not be combined for best evidence synthesis or meta-analysis due to distinct differences in the strategies, populations, or outcomes between each study.

Strengths

This review examined a full spectrum of strategies that were implemented and empirically evaluated to tackle the opioid crisis in North America and to maintain the appropriate use of opioids in improving pain and function among patients with chronic pain. Few systematic reviews in this field have conducted comprehensive grey literature searches. In doing this, we compiled a comprehensive repository of relevant publications that included peer-reviewed articles and empirical evidence from grey literature. We conducted a narrative synthesis to describe the interventions and a quantitative analysis to assess the effectiveness of each intervention, and we were able to calculate effect sizes and map these strategies using radar charts to visualize the data and make conclusions about the most promising strategies. In addition, we produced a framework that stratifies each intervention by impact factor and type of outcome assessed. This unique framework emphasizes the importance of both elements; for example, even a small impact on overdose and death holds remarkable significance. Decision makers can prioritize the categories of outcome according to their objectives and use the impact factors to determine relative effectiveness of an intervention for a particular outcome. Our study capitalizes on the heterogeneity of interventions, populations, and outcomes found in the literature, so that decision makers can appraise the various interventions in context and tailor their modifications accordingly.

Similar studies

Strategies and interventions to address the sweeping opioid crisis have been the subject of several narrative reviews, providing a broad overview of existing strategies, as well as drawing attention to more novel interventions. Narrative syntheses, however, lack comprehensive and systematic literature search strategies and, thus, are prone to publication bias.

We are aware of a handful of recent systematic reviews that have synthesized the evidence for specific types of strategies, including primary care delivery models for treating opioid use disorders, supervised dosing versus off-site consumption of opioid substitution treatment, community overdose prevention and naloxone distribution programs, supervised consumption sites, clinical strategies for reducing aberrant drug-related behavior (e.g., treatment agreements, urine drug testing), and prescription opioid policies (namely, guidelines and legislation). Consistent across four reviews was the finding that naloxone and overdose prevention programs are associated with a reduction in overdose mortality and increased odds of recovery. A recent scoping review also found mixed evidence for the effectiveness of prescription drug monitoring programs. These findings are consistent with the findings of our review.

However, most of these prior reviews employed restrictive search strategies and/or had inadequate or nonexistent quality appraisal. Only one review considered some degree of grey literature.
Only one published systematic review, to our knowledge, has considered the effectiveness of a broad range of strategies. Haegerich and colleagues examined the impact of state policy and systems-level interventions on prescriber and patient behavior and health outcomes (e.g., overdoses), finding low-quality evidence of positive effects for PMPs, insurer strategies, pain clinic legislation, clinical guidelines, and naloxone distribution. There was also little evidence of effect for safe storage and disposal strategies and patient education. The review by Haegerich et al., though comprehensive in scope, also had limitations, including limiting searches to Medline, searches up to 2014, including only English-language studies, and primarily relying on studies from the United States.

**Future research**

Many promising strategies have already been implemented in the past couple of years in North America, such as naloxone distribution. There is a need to conduct empirical studies of more novel interventions. We found many publications that described various novel strategies, but they were excluded because they lacked an empirical measure to assess the impact on any of the outcomes of interest. A list of the excluded studies can be obtained upon request.

Future studies should aim at high methodological standards. In nonexperimental studies where randomization and separate control groups are not possible, it would be ideal to conduct interrupted time series or controlled before and after as the study design. Interrupted time series and controlled before and after are particularly useful in the context of public health interventions. Nonexperimental or observational studies should also discuss concurrent interventions or policy changes that may affect the population or region of interest. If no other concomitant interventions were introduced, studies should report either the measured outcome at the pre-intervention time point or the literature value that is relevant to the population or region of interest. Rather than only reporting the final change in the outcomes, we recommend that future studies report the measured outcomes at both the pre- and post-intervention time points. Studies should also report the sample size or population size, so that it is possible to calculate the variance of the effect sizes. Lastly, we recommend that future studies include a cost–benefit analysis of an intervention, so that decision makers and policymakers can better assess the relative cost-effectiveness and feasibility of the interventions.

**Conclusions**

This broad-scope systematic review found some promising strategies to tackle the opioid crisis in North America. The content of these strategies included education, clinical practice changes, naloxone distribution, PMPs, regulations, collaborations, public health, and opioid substitution treatments. The most common target population of these strategies was health care professionals, followed by patients/opioid users and the general public. Twenty-nine percent of the strategies described some type of unintended consequence, which affected the target population, the health care professionals involved in the implementation of the strategy, or the public in general. There is a need for high-quality studies in this area to assess the impact of novel strategies on various outcomes, including appropriate use of opioids and reduction of misuse, abuse, opioid use disorder, diversion, overdoses, and deaths related to opioids.

**Acknowledgments**

We thank the following individuals for their support in obtaining the funding and/or for volunteering their time to conduct grey literature searches, article screening, and quality appraisal: Heather Dickinson, Regie Caverson, Heather Divine, R. Thomas Girling, Marty McLeod, Amy Porah-Waller, Anita Srivastava, Norman Buckley, Diane Vermilyea, Arun Radhakrishnan, Soudeh Taghdiri, Joanna Liu, Andrew Wong, Melanie Fortune, Fernanda Miyumi, Abdul Hamad, and Cynthia Chen.

**Funding**

We acknowledge funding from the Canadian Institutes for Health Research to conduct this systematic review (#KSU-126318).

**Declaration of interest statement**

The authors have no conflict of interests to declare.

**References**

1. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315(15):1624–1645. doi:10.1001/jama.2016.1464.

2. Public Health Agency of Canada. Statement from the co-chairs of the federal, provincial and territorial special advisory committee on the epidemic of opioid overdoses; 2017 [accessed 2017 Nov 27]. https://www.canada.ca/en/publichealth/news/2017/09/statement_from_the_co-chairs_of_the_federal_provincial_and_territorial.html.
3. Public Health Agency of Canada. Statement from the co-chairs of special advisory committee on the epidemic of opioid overdoses on updates to opioid-related mortality data; 2017 Dec 18 [accessed 2017 Dec 30]. http://www.newswire.ca/news-releases/statement-from-the-co-chairs-of-special-advisory-committee-on-the-epidemic-of-opioid-overdoses-on-updates-to-opioid-related-mortality-data-664993543.html.

4. Canadian Institute for Health Information. Pan-Canadian trends in the prescribing of opioids, 2012 to 2016. 2017 [accessed 2017 Dec 26]. https://www.cihi.ca/sites/default/files/document/pan-canadian-trends-opioid-prescribing-2017-en-web.pdf.

5. Canadian Pain Society. Position statement on opioid analgesics in pain management—2015 update. Pain Res Manag. 2015;20(6):287. doi:10.1155/2015/251464.

6. Lynch ME, Fischer B. Prescription opioid abuse: what is the real problem and how do we fix it? Can Fam Physician. 2011;57:1241–1242, e403–e405.

7. Finestone HM, Juurlink DN, Power B, Gomes T, Pimlott N. Opioid prescribing is a surrogate for inadequate pain management resources. Can Fam Physician. 2016;62:465–468.

8. Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: what actually works? A systematic review. PLoS One. 2017;12(10):e0186315. doi:10.1371/journal.pone.0186315.

9. Saulle R, Vecchi S, Gowing L. Supervised dosing with a long-acting opioid medication in the management of opioid dependence. Cochrane Database Syst Rev. 2017;4:CD011983.

10. McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016;111(7):1177–1187. doi:10.1111/add.13117.

11. Mueller SR, Walley AY, Calcaterra SL, Glanz JM,Binswanger IA. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. Subst Abuse. 2015;36(2):240–253. doi:10.1080/08897077.2015.1010032.

12. Giglio RE, Li G, DiMaggio CJ. Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis. Inj Epidemiol. 2015;2(1):10. doi:10.1186/s40621-015-0041-8.

13. Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8(3):153–163. doi:10.1097/ADM.0000000000000034.

14. Starrels JL, Becker WC, Allford DP, Kapoor A, Williams AR, Turner BJ. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010;152(11):712–720. doi:10.7326/0003-4819-152-11-20100610-00004.

15. Argoff CE, Kahan M, Sellers EM. Preventing and managing aberrant drug-related behavior in primary care: systematic review of outcomes evidence. J Opioid Manag. 2014;10(2):119–134. doi:10.5055/jom.2014.0201.

16. Beaudoin FL, Banerjee GN, Mello MJ. State-level and system-level opioid prescribing policies: the impact on provider practices and overdose deaths, a systematic review. J Opioid Manag. 2016;12(2):109–118. doi:10.5055/jom.2016.0322.

17. Furlan A, Irvin E, Van Eerd D, Carnide N, Munhall C, Kim J, Mahood, MacDonald S. Strategies to support the appropriate use of prescription opioids: a systematic review using narrative and best evidence synthesis methods. PROSPERO. 2014;CRD42014009675. http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_record.asp?ID=CRD42014009675.

18. Substance Abuse and Mental Health Services Administration. Results from the 2016 national survey on drug use and health: detailed tables. 2017 [accessed 2018 Mar 7]. https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.htm.

19. Dhalla IA, MAMDANI MM, SIVILLOTTI ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009;181(12):891–896. doi:10.1503/cmaj.090784.

20. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;65(50–51):1378–1382. doi:10.15585/mmwr.mm6450a3.

21. Hodgson A, Normandin S. Grey matters! Finding grey literature. Ottawa (Canada): Canadian Agency for Drugs and Technologies in Health; 2008.

22. Review manager (RevMan) [Computer program]. Version 5.3. Copenhagen (Denmark): The Nordic Cochrane Centre: The Cochrane Collaboration; 2014. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=9675.

23. Borenstein M. Effect sizes based on means. Introduction to meta-analysis. Hoboken, NJ: John Wiley & Sons; 2009. p. 21–32.

24. Rosenthal R. Meta-analytic procedures for social research. Newbury Park (CA): Sage; 1991.

25. Rosenthal R. Parametric measures of effect size. In: Cooper H, Hedges LV, editors. The handbook of research synthesis. New York (NY): Sage; 1994. p. 231–244.

26. Rosnow RL. Effect sizes for experimenting psychologists. Can J Exp Psychol. 2003;57(3):221–237. doi:10.1037/h0087427.

27. Hedges LV, Olkin I. Statistical methods for meta-analysis. 1st ed. San Diego, CA: Academic Press; 1985.

28. Glass G, Smith ML, McGaw B. Meta-analysis in social research. Beverly Hills (CA): Sage; 1981.

29. Borenstein M. Converting among effect sizes. In: Cooper H, Hedges LV, editors. The handbook of research synthesis. New York (NY): Sage; 1994. p. 231–244.

30. Cohen J. Statistical power analysis for the behavioural sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.

31. Gonzalez AM III, Kolbasovsky A. Impact of a managed controlled-opioid prescription monitoring program on care coordination. Am J Manag Care. 2012;18:516–524.
32. Jamison RN, Ross EL, Michena E, Chen LQ, Holcomb C, Wasan AD. Substance misuse treatment for high-risk chronic pain patients on opioid therapy: a randomized trial. Pain. 2010;150(3):390–400. doi:10.1016/j.pain.2010.02.033.

33. Naliboff BD, Wu SM, Schieber B, Bolus R, Pham Q, Baria A, Aragaki D, Van Vort W, Davis F, Shekelle P. A randomized trial of 2 prescription strategies for opioid treatment of chronic nonmalignant pain. J Pain. 2011;12(2):288–296. doi:10.1016/j.jpain.2010.09.003.

34. Otto C, Crackau B, Löhrmann I, Zahradnik A, Bischof G, John U, Rumpf HJ. Brief intervention in general hospital for problematic prescription drug use: 12-month outcome. Drug Alcohol Depend. 2009;105(3):221–226. doi:10.1016/j.drugalcdep.2009.07.010.

35. Saitz R, Palfai TP, Cheng DM, Alfond DP, Bernstein JA, Lloyd-Travaglini CA, Meli SM, Chaisson CE, Samet JH. Screening and brief intervention for drug use in primary care: the ASPIRE randomized clinical trial. JAMA. 2014;312(5):502–513. doi:10.1001/jama.2014.7862.

36. Spoth R, Redmond C, Clair S, Shin C, Greenberg M, Feinberg M. Preventing substance misuse through community–university partnerships; randomized controlled trial outcomes 4 1/2 years past baseline. Am J Prev Med. 2011;40(4):440–447. doi:10.1016/j.amepre.2010.12.012.

37. Spoth R, Trudeau L, Shin C, Ralston E, Redmond C, Greenberg M, Feinberg M. Longitudinal effects of universal preventive intervention on prescription drug misuse: three randomized controlled trials with late adolescents and young adults. Am J Public Health. 2013;103(4):665–672. doi:10.2105/AJPH.2012.301209.

38. Spoth R, Trudeau L, Shin C, Redmond C. Long-term effects of universal preventive interventions on prescription drug misuse. Addiction. 2008;103(7):1160–1168. doi:10.1111/j.1360-6043.2008.02160.x.

39. Sullivan MD, Leigh J, Gaster B. Brief report: training interns in shared decision making about chronic opioid treatment for noncancer pain. J Gen Intern Med. 2006;21(4):360–362. doi:10.1111/j.1525-1497.2006.00352.x.

40. Ablaihed L, Barrueto J, Pimentel L, Comer A, Browne BJ, Hirshon JM. High risk care plans effectively decrease emergency department resource utilization. Ann Emerg Med. 2014;64(Suppl. 1):S4. doi:10.1016/j.annemermed.2014.07.033.

41. Albert S, Brason FW II, Sanford CK, Dasgupta N, Graham J, Lovette B. Project Lazarus: community-based overdose prevention in rural North Carolina. Pain Med. 2011;12(Suppl. 2):S77–S85. doi:10.1111/j.1526-4327.2011.01128.x.

42. Andrews LB, Bridgeman MB, Dalal KS, Abazia D, Lau C, Goldsmith DF, John DS. Implementation of a pharmacist-driven pain management consultation service for hospitalised adults with a history of substance abuse. Int J Clin Pract. 2013;67(12):1342–1349. doi:10.1111/jcpr.12311.

43. Barry DT, Cutter CJ, Beitel M, Liong C, Schottenfeld RS. Cognitive-behavioral therapy and educational counseling for chronic pain and opioid dependence. Drug Alcohol Depend. 2015;146:e218–e219.

44. Bujold E, Huff J, Staton EW, Pace WD. Improving use of narcotics for nonmalignant chronic pain: a lesson from Community Care of North Carolina. J Opioid Manag. 2012;8(6):363–367. doi:10.5055/jom.

45. Burchman SL, Pagel PS. Implementation of a formal treatment agreement for outpatient management of chronic nonmalignant pain with opioid analogesics. J Pain Symptom Manage. 1995;10(7):556–563. doi:10.1016/0885-3924(95)00085-D.

46. Chelminski PR, Ives TJ, Felix KM, Prakken SD, Miller TM, Perhac JS, Malone RM, Bryant ME, DeVault DA, Pignone MP. A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Serv Res. 2005;5(1):3. doi:10.1186/1472-6963-5-3.

47. Cicero TJ, Inciardi JA, Adams EH, Geller A, Senay EC, Woody GE, Muñoz A. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994–2004. Pharmacoepidemiol Drug Saf. 2005;14(12):851–859. doi:10.1002/pds.1113.

48. Cochella S, Bateman K. Provider detailing: an intervention to decrease prescription opioid deaths in Utah. Pain Med. 2011;12(Suppl. 2):S73–S76. doi:10.1111/j.1526-4367.2011.01125.x.

49. Davis C, Walley A, Bridger C. Lessons learned from the expansion of naloxone access in Massachusetts and North Carolina. J Law Med Ethics. 2015;43(1):19–22. doi:10.1111/jlme.12208.

50. Delcher C, Wagenaar AC, Goldberger BA, Cook RL, Maldonado-Molina MM. A abrupt decline in oxycodone-caused mortality after implementation of Florida’s Prescription Drug Monitoring Program. Drug Alcohol Depend. 2015;150:63–68. doi:10.1016/j.drugalcdep.2015.02.010.

51. DiPaula BA, Menachery E. Physician–pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients. J Am Pharm Assoc (2003). 2015;55(2):187–192. doi:10.1331/JAPhA.2015.14177.

52. Doe-Simkins M, Quinn E, Xuan Z, Sorensen-Alawad H, Hackman H, Ozonoff A, Walley AY. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health. 2014;14:297. doi:10.1186/1471-2458-14-297.

53. Doe-Simkins M, Walley AY, Epstein A, Moyer P. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health. 2009;99(5):788–791. doi:10.2105/AJPH.2008.146647.

54. Dormuth CR, Miller TA, Huang A, Mandani MM, Juurlink DN. Effect of a centralized prescription network on inappropriate prescriptions for opioid analogesics and benzodiazepines. CMAJ. 2012;184(16):E852–E856. doi:10.1503/cmaj.120465.

55. Dwyer K, Walley AY, Langlois BK, Mitchell PM, Lin SC, Nelson KP, Cromwell J, Bernstein E. Opioid education and naloxone rescue kits in the emergency department. Western Journal of Emergency Medicine. 2015 May; 16(3):381–384.
56. Franklin GM, Mai J, Turner J, Sullivan M, Wickizer T, Fulton-Kehoe D. Bending the prescription opioid dosing and mortality curves: impact of the Washington State opioid dosing guideline. Am J Ind Med. 2012;55(4):325–331. doi:10.1002/ajim.v55.4.

57. Fulton-Kehoe D, Sullivan MD, Turner JA, Garg RK, Bauer AM, Wickizer TM, Franklin GM. Opioid poisonings in Washington state medicare: Trends, dosing, and guidelines. Medical care. 2015;53(8):679–685.

58. Furlan AD, MacDougall P, Pellerin D, Shaw K, Spitzig D, Wilson G, Wright J. Overview of four prescription monitoring/review programs in Canada. Pain Res Manag. 2014;19(2):102–106. doi:10.1155/2014/634171.

59. Garcia MM, Angelini MC, Thomas T, Lenz K, Jeffrey M, Altschul S, Shook C. Prescription opioid abuse, chronic pain, and primary care: a co-occurring disorders clinic in the chronic disease model. J Subst Abuse Treat. 2011;41(3):203–208. doi:10.1016/j.jsat.2011.04.008.

60. Gaston RL, Best D, Manning V, Day E. Can we prevent drug related deaths by training opioid users to recognize and manage overdoses? Harm Reduct J. 2009;6:26. doi:10.1186/1477-7517-6-26.

61. Goldberg KC, Simel DL, Oddone EZ. Effect of an opioid management system on opioid prescribing and unscheduled visits in a large primary care clinic. J Clin Outcomes Manag. 2005;12:621–628.

62. Gray J, Hagemeier N, Brooks B, Alamian A. Prescription disposal practices: a 2-year ecological study of drug drop box donations in Appalachia. Am J Public Health. 2015;105(9):e89–e94. doi:10.2105/ AJPH.2015.302689.

63. Green TC, Dauria EF, Bratberg J, Davis CS, Walley AY. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct J. 2015;12:Art–9.

64. Green TC, Mann MR, Bowman SE, Zaller N, Soto X, Gadea J, Cordy C, Kelly P, Friedmann PD. How does use of a prescription monitoring program change pharmacy practice? J Am Pharm Assoc. 2013;53(3):273–381. doi:10.1331/JAPhA.2013.12094.

65. Gugelmann H, Shofer FS, Meisel ZF, Perrone J. Multidisciplinary intervention decreases the use of opioid medication discharge packs from 2 urban EDs. Am J Emerg Med. 2013;31(9):1343–1348. doi:10.1016/j.ajem.2013.06.002.

66. Husk G, Nguyen T, Jellinek-Cohen S, Li M, Heller M. The effect of a statewide prescription monitoring program on ed prescribing of controlled substances. Acad Emerg Med. 2014;21:S310.

67. James J, Klein JW, Chew L, Merrill J, Jackson SL. A comprehensive clinic-based strategy to promote safe opioid prescribing for chronic non-cancer pain in the primary care setting. J Gen Intern Med. 2014;29:S472.

68. Johnson H, Paulozzi L, Porucznik C, Mack K, Herter B. Decline in drug overdose deaths after state policy changes—Florida, 2010–2012. MMWR Morb Mortal Wkly Rep. 2014;63:569–574.

69. Kanate D, Folk D, Cicrone S, Gordon J, Kirlew M, Veale T, Bocking N, Rea S, Kelly L. Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence: evaluating outpatient buprenorphine–naloxone substitution therapy in the context of a First Nations healing program. Can Fam Physician. 2015;61(2):160–165.

70. Katzman J, Comerci GD, Landen M, Loring L, Jenkuszky SM, Arora S, Kalishman S, Marr L, Camarata C, Duhigg D. Rules and values: a coordinated regulatory and educational approach to the public health crises of chronic pain and addiction. Am J Public Health. 2014;104(8):1356–1362. doi:10.2105/AJPH.2014.301881.

71. Keast SL, Nesser N, Farmer K. Strategies aimed at controlling misuse and abuse of opioid prescription medications in a state Medicaid program: a policymaker’s perspective. Am J Drug Alcohol Abuse. 2015;41(1):1–6. doi:10.3109/00952990.2014.988339.

72. Ketcham EM, Fredella A, Malone M, Ketcham C, Larkin GL. A novel Six-Sigma-based multidisciplinary administrative intervention reduces opioid-seeking patient emergency department recidivism. Ann Emerg Med. 2014;64(4 Suppl. 1):S99. doi:10.1016/j.annemergmed.2014.07.306.

73. Kim E, Genes N, Coupet M. Effect of mandatory prescription drug monitoring program on emergency department prescribing of scheduled drugs. Ann Emerg Med. 2014;64(4 Suppl. 1):S81–S82. doi:10.1016/j.annemergmed.2014.07.254.

74. Lamb L, Pereira JX, Shir Y. Nurse case management program of chronic pain patients treated with methadone. Pain Manag Nurs. 2007;8(3):130–138. doi:10.1016/j.pmn.2007.05.002.

75. Larochelle MR, Zhang F, Ross-Degnan D, Wharam JF. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA Intern Med. 2015;175(6):978–987. doi:10.1001/jamainternmed.2015.0914.

76. Leece P, Hopkins S, Marshall C, Orkin A, Gassanov M, Shahin R. Development and implementation of an opioid overdose prevention and response program in Toronto, Ontario. Can J Public Health. 2013;104(3):e200–e204. doi:10.17269/cjph.104.3788.

77. Lofwall MR, Wunsch MJ, Nuzzo PA, Walsh SL. Efficacy of continuing medical education to reduce the risk of buprenorphine diversion. J Subst Abuse Treat. 2011;41(3):321–329. doi:10.1016/j.jstat.2011.04.008.

78. Manchikanti L, Manchukonda R, Damron KS, Brandon D, McNamus CD, Cash K. Does adherence to continuing medical education reduce the risk of buprenorphine abuse? J. Training rural practitioners to use buprenorphine: using the Change Book to facilitate technology transfer. J Subst Abuse Treat. 2004;26(3):203–208. doi:10.1016/S0740-5472(03)00247-2.

79. Pade PA, Cardon KE, Hoffman RM, Geppert CMA. Prescription opioid abuse, chronic pain, and primary care: a co-occurring disorders clinic in the chronic disease model. J Subst Abuse Treat. 2012;43(4):446–450. doi:10.1016/j.jstat.2012.08.010.

80. Paone D, Tuazon E, Kattan J, Nolan ML, O’Brien DB, Dowell D, Farley TA, Kunins HV. Decrease in rate of opioid analogic overdose deaths—Staten Island, New York City, 2011–2013. MMWR Morb Mortal Wkly Rep. 2015;64(18):491–494.
82. Piper TM, Rudenstine S, Stancliff S, Sherman S, Nandi V, Clear A, Galea S. Overdose prevention for injection drug users: lessons learned from naloxone training and distribution programs in New York City. Harm Reduct J. 2007;4:3. doi:10.1186/1747-7171-4-3.

83. Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart RC, Bucher Bartelson B. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012;13(3):434–442. doi:10.1111/j.1526-4637.2012.01327.x.

84. Ringwalt C, Garrettson M, Alexandria S. The effects of North Carolina’s prescription drug monitoring program on the prescribing behaviors of the state’s providers. J Prim Prev. 2015;36(2):131–137. doi:10.1007/s10935-014-0381-0.

85. Saenger M, Duva IM, Abraham C, Porter R, D’Antignac V. Inter-professional “community of practice” to implement “universal precautions” for opioid safety within the patient centered medical home. J Gen Intern Med. 2013;28:S440–S441.

86. Sandoo VW, Mcaughrty P, Al-Hadad A, Mavani F, Zheng T, Conroy S. Stop start tool for improving prescribing amongst older inpatients: results from a three year audit cycle. Age Ageing. 2011;40:ii25.

87. Schlicher N. Reforming emergency care: experts put focus on value, better alignment. ED Manag. 2013;21:68–79.

88. Srivastava A, Kahan M, Jiwa A. Prescription opioid use and misuse: piloting an educational strategy for rural primary care physicians. Can Fam Physician. 2012;58:e210–e216.

89. Stover H. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res. 2010;16(1):44–54. doi:10.1159/000320576.

90. Summers P, Martin C, Quigley-Neveares A. The impact of an educational group session on opioid treatment agreement violations. J Pain. 2014;15(Suppl 2):S40.

91. Taylor SE, Braithberg G, Lugt J. Multifaceted education initiative minimizes pethidine prescribing in the emergency department. Emerg Med Australas. 2007;19(1):25–30. doi:10.1111/emm.2007.19.issue-1.

92. Thomas CP, Kim M, Kelleher SJ, Nikitin RV, Kreiner PW, McDonald A, Carrow GM. Early experience with electronic prescribing of controlled substances in a community setting. J Am Med Inform Assoc. 2013;20(e1):e44–e51. doi:10.1136/amiajnl-2012-001499.

93. Walley AY, Xuan Z, Hackman HH, Quinn E, Dose-Simkins M, Sorensen-Alawad A, Ruiz S, Ozonoff A. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174. doi:10.1136/bmj.f174.

94. Wheeler E, Davidson PJ, Stephen Jones T, Irwin KS. Community-based opioid overdose prevention programs providing naloxone—United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61:101–105.

95. Wiedemer NL, Harden PS, Arndt IO, Gallagher RM. The opioid renewal clinic: a primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Med. 2007;8(7):573–584. doi:10.1111/j.1526-4637.2006.00254.x.

96. Kunins HV. Abuse-deterrent opioid formulations: part of a public health strategy to reverse the opioid epidemic. JAMA Intern Med. 2015;175(6):987–988. doi:10.1001/jamainternmed.2015.0939.

97. Zahradnik A, Otto C, Crackau B, Löhrmann I, Bischof G, John U, Rumpf HJ. Randomized controlled trial of a brief intervention for problematic prescription drug use in non-treatment-seeking patients. Addiction. 2009;104(1):109–117. doi:10.1111/j.1360-0443.2008.02421.x.

98. Fischer B, Jones W, Murphy Y, Ialomiteanu A, Rehm J. Recent developments in prescription opioid-related dispensing and harm indicators in Ontario, Canada. Pain Physician. 2015;18:E659–E662.

99. Hawk KE, Vaca FE, D’Onofrio G. Reducing fatal opioid overdose: prevention, treatment and harm reduction strategies. Yale J Biol Med. 2015;88:235–245.

100. Nadelmann E, LaSalle L. Two steps forward, one step back: current harm reduction policy and politics in the United States. Harm Reduct J. 2017;14(1):37. doi:10.1186/s12954-017-0157-y.

101. Soelberg CD, Brown RE Jr, Du Vivier D, Meyer JE, Ramachandran BK. The U.S. opioid crisis: current federal and state legal issues. Anesth Analg. 2017;125(5):1675–1681. doi:10.1213/ANE.0000000000002403.

102. Potier C, Laprevote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014;145:48–68. doi:10.1016/j.drugalcdep.2014.10.012.

103. Kennedy MC, Karamouzian M, Kerr T. Public health and public order outcomes associated with supervised drug consumption facilities: a systematic review. Curr HIV/AIDS Rep. 2017;14(5):161–183. doi:10.1007/s11904-017-0363-y.

104. Finley EP, Garcia A, Rosen K, McGeary D, Pugh MJ, Potter JS. Evaluating the impact of prescription drug monitoring program implementation: a scoping review. BMC Health Serv Res. 2017;17(1):420. doi:10.1186/s12913-017-2354-5.

105. Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM. What we know, and don’t know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend. 2014;145:34–47. doi:10.1016/j.drugalcdep.2014.10.001.